Andrea Brugnolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128079/publications.pdf

Version: 2024-02-01

218677 233421 2,206 60 26 45 citations g-index h-index papers 60 60 60 3419 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Stratification Tools for Diseaseâ€Modifying Trials in Prodromal Synucleinopathy. Movement Disorders, 2022, 37, 52-61.	3.9	7
2	Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1263-1274.	6.4	12
3	The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer's Disease and Frontotemporal Dementia. Biomedicines, 2022, 10, 544.	3.2	8
4	The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. Journal of Alzheimer's Disease, 2022, 87, 887-899.	2.6	1
5	The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1945-1955.	2.8	1
6	Rapid eye movement sleep behavior disorder: A proofâ€ofâ€concept neuroprotection study for prodromal synucleinopathies. European Journal of Neurology, 2021, 28, 1210-1217.	3.3	9
7	Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2834-2845.	6.4	22
8	Neuroprogression as an Illness Trajectory in Bipolar Disorder: A Selective Review of the Current Literature. Brain Sciences, 2021, 11, 276.	2.3	31
9	The fate of patients with REM sleep behavior disorder and mild cognitive impairment. Sleep Medicine, 2021, 79, 205-210.	1.6	19
10	Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 2293-2302.	3.9	7
11	Polysomnographic correlates of sleep disturbances in de novo, drug naÃ⁻ve Parkinson's Disease. Neurological Sciences, 2021, , 1.	1.9	2
12	Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). Diagnostics, 2021, 11, 108.	2.6	3
13	The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease. Neurobiology of Aging, 2020, 96, 117-127.	3.1	11
14	Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. Cortex, 2020, 130, 401-412.	2.4	16
15	Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study. Journal of Alzheimer's Disease, 2020, 74, 865-874.	2.6	21
16	The Italian Version of the Test Your Memory (TYM-I): A Tool to Detect Mild Cognitive Impairment in the Clinical Setting. Frontiers in Psychology, 2020, 11, 614920.	2.1	4
17	Cognitive impairment in late life bipolar disorder: Risk factors and clinical outcomes. Journal of Affective Disorders, 2019, 257, 166-172.	4.1	19
18	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14

#	Article	IF	CITATIONS
19	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging, 2019, 76, 9-17.	3.1	23
20	18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2073-2083.	6.4	29
21	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. Movement Disorders, 2017, 32, 1738-1747.	3.9	43
22	Early identification of MCI converting to AD: a FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2042-2052.	6.4	83
23	Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis?. Alzheimer Disease and Associated Disorders, 2016, 30, 183-185.	1.3	8
24	P4-190: 18FDG PET Predicts Time to Disease Milestones in a Naturalistic Population of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease. , 2016, 12, P1094-P1095.		0
25	Predicting the transition from normal aging to Alzheimer's disease: A statistical mechanistic evaluation of FDG-PET data. Neurolmage, 2016, 141, 282-290.	4.2	36
26	Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. Parkinsonism and Related Disorders, 2016, 29, 47-53.	2.2	57
27	Parkinson's Disease Sleep Scale 2: application in an Italian population. Neurological Sciences, 2016, 37, 283-288.	1.9	21
28	An updated Italian normative dataset for the Stroop color word test (SCWT). Neurological Sciences, 2016, 37, 365-372.	1.9	49
29	A normative study of the Italian printed word version of the free and cued selective reminding test. Neurological Sciences, 2015, 36, 1127-1134.	1.9	21
30	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage: Clinical, 2015, 7, 34-42.	2.7	85
31	Brain 18F-DOPA PET and cognition in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1062-1070.	6.4	23
32	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	2.6	67
33	Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 764-775.	6.4	30
34	Metabolic Correlates of Rey Auditory Verbal Learning Test in Elderly Subjects with Memory Complaints. Journal of Alzheimer's Disease, 2014, 39, 103-113.	2.6	39
35	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	5.0	108
36	The Short Cognitive Evaluation Battery in Cognitive Disorders of the Elderly – Italian Version. Dementia and Geriatric Cognitive Disorders, 2012, 33, 255-265.	1.5	3

#	Article	IF	CITATIONS
37	What predicts cognitive decline in de novo Parkinson's disease?. Neurobiology of Aging, 2012, 33, 1127.e11-1127.e20.	3.1	34
38	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	3.1	108
39	Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD). Journal of the Neurological Sciences, 2011, 310, 31-35.	0.6	19
40	Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2209-2218.	6.4	32
41	The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. International Psychogeriatrics, 2010, 22, 984-994.	1.0	195
42	Unawareness of Memory Deficit in Amnestic MCI: FDG-PET Findings. Journal of Alzheimer's Disease, 2010, 22, 993-1003.	2.6	59
43	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	6.4	95
44	Cognitiveâ€nigrostriatal relationships in de novo, drugâ€naà ve Parkinson's disease patients: A [lâ€123]FPâ€CIT SPECT study. Movement Disorders, 2010, 25, 35-43.	3.9	83
45	Impaired access to semantic memory for the cognition of geographic space in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2010, 50, 198-201.	3.0	2
46	The Reversed Clock Drawing Test Phenomenon in Alzheimer's Disease: A Perfusion SPECT Study. Dementia and Geriatric Cognitive Disorders, 2010, 29, 1-10.	1.5	8
47	MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings. Current Alzheimer Research, 2010, 7, 287-294.	1.4	41
48	Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study. Movement Disorders, 2009, 24, 414-421.	3.9	63
49	The factorial structure of the mini mental state examination (MMSE) in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2009, 49, 180-185.	3.0	34
50	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	2.6	42
51	Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2191-2202.	6.4	77
52	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	1.5	167
53	The need of appropriate brain SPECT templates for SPM comparisons. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2008, 52, 89-98.	0.7	15
54	Cortical sources of awake scalp EEG in eating disorders. Clinical Neurophysiology, 2007, 118, 1213-1222.	1.5	23

#	Article	IF	CITATION
55	Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: Correlations between sympathovagal activity, clinical features, and leptin levels. Journal of Endocrinological Investigation, 2007, 30, 356-362.	3.3	69
56	99mTc-HMPAO and 99mTc-ECD brain uptake correlates of verbal memory in Alzheimer's disease. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51, 357-63.	0.7	12
57	The Von Restorff effect in ageing and Alzheimer's disease. Neurological Sciences, 2006, 27, 166-172.	1.9	15
58	Stroop interference task and single-photon emission tomography in anorexia: A preliminary report. International Journal of Eating Disorders, 2005, 38, 323-329.	4.0	20
59	Global cognitive impairment should be taken into account in SPECT–neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1186-1192.	6.4	10
60	Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clinical Neurophysiology, 2005, 116, 364-375.	1.5	51